Revance Therapeutics Inc (NASDAQ:RVNC)
| 29.07 Delayed Data As of 3:59pm ET |  -0.18 / -0.62%Today’s Change | 22.89 Today|||52-Week Range 34.62 | +2.58% Year-to-Date |
Latest RVNC News | Press Releases
| Analysts Estimate Revance Therapeutics, Inc. (RVNC) to Report a Decline in Earnings: What to Look Out for Jul 29 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 29.25 |
| Today’s open | 29.14 |
| Day’s range | 28.82 - 29.55 |
| Volume | 10,551 |
| Average volume (3 months) | 402,257 |
| Market cap | $2.1B |
Data as of 3:59pm ET, 07/30/2021
Growth & Valuation
| Earnings growth (last year) | -32.56% |
| Earnings growth (this year) | +6.32% |
| Earnings growth (next 5 years) | +192.00% |
| Revenue growth (last year) | +3,610.65% |
| P/E ratio | NM |
| Price/Sales | 107.27 |
| Price/Book | 5.54 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| IRWDIronwood Pharmaceuti... | +0.12 | +0.87% |
| ---- | ||
| LGNDLigand Pharmaceutica... | -5.56 | -4.66% |
| QTRXQuanterix Corp | -0.58 | -1.08% |
Data as of 3:59pm ET, 07/30/2021
Financials
| Next reporting date | August 5, 2021 |
| EPS forecast (this quarter) | -$0.96 |
| Annual revenue (last year) | $15.3M |
| Annual profit (last year) | -$282.1M |
| Net profit margin | -1,840.71% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
No executives to display |
Corporate headquarters Nashville, Tennessee |
Forecasts
